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Abstract
Background: Fetuin-A/AHSH is a novel hepatokine that acts as a vascular calcification inhibitor and as an
endogenous TLR-4 ligand. Fetuin-A may act as a positive or negative acute phase protein (APP) in disease
conditions. The relationship between circulatory fetuin-A and inflammatory biomarkers in type-2 diabetes
(T2D) remains controversial. Therefore, the purpose of this study was to determine the plasma fetuin-A levels
in 53 T2D (BMI = 29.7 ± 4.5 kg/m2) and 72 non-diabetic individuals (BMI = 28.2 ± 5.8 kg/m2) using premixed
38-plex MAP human cytokine/chemokine magnetic bead immunoassays and the data (mean ± SEM) were
statistically analyzed to determine Pearson’s correlation (r) between fetuin-A and detected analytes; P-values
≤0.05 were considered significant.
Results: The data show that plasma fetuin-A levels were comparable in both groups (P = 0.27) and in T2D
individuals, fetuin-A associated negatively (P≤ 0.05) with a large number of proinflammatory cytokines/chemokines
and activation biomarkers including TNF-α, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-3, IL-4, IL-7, IL-9, IL-12p40/p70, IL-15,
CCL-2, CCL-4, CCL-11, CCL-22, CXCL-8, CX3CL-1, EFF-2, EGF, G-CSF, GM-CSF, GRO, sCD40L, and VEGF. In non-diabetics,
fetuin-A also correlated positively with certain TH2 cytokines (IL-5, IL-13) and chemokines (CCL-3, CCL-5, CCL-7).
Notably, in vitro fetuin-A production was significantly suppressed in HepG2 cells treated with TNF-α, IL-1β, and IFN-γ
which supported the clinical findings of a negative association between fetuin A and inflammatory mediators.
Conclusions: The negative association between circulatory fetuin-A and systemic inflammatory mediators in T2D
patients suggests that plasma fetuin-A may have predictive significance as a negative APP in metabolic disease.
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Background
Fetuin-A, also known as α-2 Heremans-Schmid glyco-
protein (AHSG), is a member of cystatin superfamily of
protease inhibitors and is a major human secretory pro-
tein of hepatic origin with multiple normal biological as
well as pathological functions including inhibition of
vascular calcification, bone metabolism regulation, con-
trol of protease activity, insulin resistance, keratinocyte
migration, and breast tumor cell proliferative signaling
[1]. It is a highly expressed glycoprotein in various fetal
tissues whereas it is mainly expressed by the liver in
adults [2]. Fetuin-A acts as an endogenous ligand for the
innate immune Toll-like receptor (TLR)-4 and it also
binds to β-subunit of insulin receptor to inactivate the
insulin receptor tyrosine kinase for modulating insulin
signaling [3].
The emerging evidence weighs in with both the pro-
and anti-inflammatory attributes of fetuin-A. As a posi-
tive acute phase protein (APP), fetuin-A was reported to
induce the expression of inflammatory cytokines in adi-
pocytes and macrophages and was regarded as an
inflammatory marker [4]. On the other hand, as a nega-
tive APP, fetuin-A glycoprotein was found to play a pro-
tective or anti-inflammatory role in various disease
conditions such as infection, sepsis, endotoxemia,
trauma, cerebral ischemic injury, autoimmune disorders,
and Alzheimer’s disease [3].
Type-2 diabetes (T2D) is marked by a state of chronic
low-grade inflammation called metabolic inflammation
and the predictive value of circulatory fetuin-A as a posi-
tive or a negative APP in T2D-associated metabolic in-
flammation remains controversial [5, 6]. Therefore, the
aim of the study was to find the relationship between
plasma fetuin-A and signature inflammatory mediators
and biomarkers in T2D patients. Herein, we report that
plasma fetuin-A levels correlated negatively with inflam-
matory cytokines/chemokines and activation biomarkers
in T2D individuals, suggesting its predictive importance
as a negative APP in metabolic inflammation.
Methods
Study population and clinical assays
This study included 53 T2D patients (aged 23–75 years)
including 11 lean with body mass index (BMI) of 23.9 ±
1.6 kg/m2, 18 overweight (BMI = 27.7 ± 1.5 kg/m2), and
24 obese individuals (BMI = 33.9 ± 2.5 kg/m2) and 72
non-diabetic individuals (aged 21–66 years) including 24
lean (BMI = 22.4 ± 1.9 kg/m2), 23 overweight (BMI =
27.1 ± 1.5 kg/m2), and 25 obese individuals (BMI = 34.8
± 3.6 kg/m2), recruited through clinics of Dasman Dia-
betes Institute, Kuwait following study approval by the
institutional ethics committee. Those of age <18 years or
with serious lung, kidney, liver, or cardiovascular disease,
hematologic or immune disorders, type-1 diabetes,
pregnancy, or malignancy were excluded. Plasma sam-
ples were analyzed for fasting plasma glucose, glycated
hemoglobin (HbA1c), total cholesterol, high- and low-
density lipoproteins, triglycerides, and adiponectin using
commercial kits following instructions as recommended
by the manufacturers. Glucose and lipid profiles were
measured using Siemens dimension RXL chemistry
analyzer (Diamond Diagnostics, Holliston, MA, USA)
and HbA1c was measured using Variant device (BioRad,
Hercules, CA, USA). T2D diagnosis was based on results
of (i) fasting plasma glucose, (ii) oral glucose tolerance
test (OGTT), and (iii) HbA1c test. Fasting blood glucose
levels of ≥126 mg/dL (≥7 mmol/L), 2 h-OGTT values of
>200 mg/dL (11.1 mmol/L), and/or HbA1C levels of
≥6.5 % on two separate tests were diagnosed by phys-
ician as T2D. Regarding anthropometric and physical
data, height and weight were measured while barefoot,
waist circumference was measured and the waist-to-hip
ratio was calculated. BMI was calculated as follows: body
weight (kg)/height (m2). An average of three blood pres-
sure readings (Omron HEM-907XL digital automatic
sphygmomanometer, Omron Healthcare Inc. IL, USA),
taken after 5–10 min rest for each, was obtained. The
whole body composition including body fat percentage,
soft lean mass and total body water was assessed (IOI
353 Body Composition Analyzer, Jawon Medical, South
Korea). Patients’ clinico-demographic data are summa-
rized in Table 1.
Plasma analytes
The circulatory levels of a panel of 38 analytes including
proinflammatory cytokines, chemokines, and activation/
growth biomarkers were assessed using premixed 38-
plex MAP human cytokine/chemokine magnetic bead
(HCYTMAG-60 K-PX38, EMD Millipore Corp, USA)
multiplex immunoassay. Data were acquired using
Luminex xMAP analyzer (Luminex 100/200 Milliplex
Analyzer, Luminex Corp. USA) following the manufac-
turer’s instructions while a digital data output processor
and Milliplex analytical software were used to determine
mean fluorescence intensity (MFI) and concentrations
(pg/mL) of analytes. The data were statistically analyzed
using unpaired t-test and the linear dependence between
two variables was assessed by Pearson’s correlation coef-
ficient (r) using GraphPad Prism software (version 6.05;
San Diego, CA, USA). All P-values ≤0.05 were consid-
ered as statistical significant.
Cell culture and measurement of in vitro fetuin-A
production
Human hepatocellular carcinoma cell line HepG2 cells
were cultured at 37 °C with 5 % CO2 in high-glucose
DMEM medium containing 10 % (v/v) fetal bovine
serum, 100 units/mL penicillin, and 100 μg/mL
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streptomycin in 6-well plates at a density of 0.25 × 106
cells/mL until about 70 % confluence and old medium
was replaced with fresh culture medium. Cell mono-
layers were treated with rhTNF-α (50 ng/mL), rhIL-1β
(10 ng/mL), rhIFN-γ (50 ng/mL), rhMCP-1 (40 ng/mL),
and rhIL-6 (100 ng/mL) and incubated at 37 °C for 24 h.
In time course experiments, HepG2 cell monolayers
were treated with rhIFN-γ (50 ng/mL), rhTNF-α (50 ng/
mL), rhIL-4 (20 ng/mL), and rhIL-10 (30 ng/mL) and
cell cultures were incubated at 37 °C for 1, 6, 12, 24, and
48 h. Cell supernatants were collected, clarified by cen-
trifugation, aliquoted, and stored at −80° until use.
Fetuin-A levels were measured in cell supernatants using
sandwich high-sensitivity ELISA (Sensitivity: <10 pg/mL;
Human fetuin-A PicoKine™ ELISA kit, Boster Biological
Technology, USA) following the manufacturer’s instruc-
tions. Briefly, after adding samples (100 μL) and stan-
dards (100 μL), plates were incubated at 37 °C for
90 min. Then, without washing, biotinylated anti-human
fetuin-A antibody (1:100 diluted; 130 μL/well) was added
and incubated at 37 °C for 60 min. Plates were washed 3
times with 0.01 M Tris-buffered saline (TBS), then
Avidin-Biotin-Peroxidase Complex (ABC) was added
(1:100 diluted; 130 μL/well) and incubated at 37 °C for
30 min. Plates were washed 5 times with TBS buffer and
after adding HRP substrate 3,3',5,5'-Tetramethylbenzi-
dine (TMB color developing agent), plates were incu-
bated at 37 °C in dark for 20–25 min. Color
development was stopped by adding TMB stop solution
(100 μL/well) and absorbance/optical density (OD) was
read at 450 nm wavelength. There was no cross
reactivity detected against bovine or fetal calf fetuin-A in
control wells containing only the culture media.
Results
Plasma fetuin-A associates negatively with the inflammatory
cytokines/chemokines and activation biomarkers
The oxidative stress and inflammatory responses in-
duced in obesity and T2D are associated with upregu-
lated circulatory levels of various proinflammatory
cytokines, chemokines, and stimulatory factors that may
act in autocrine/paracrine manners to establish a sus-
tained, low-grade chronic inflammation, called metabolic
inflammation, over time. We asked whether plasma
fetuin-A was related as a positive or negative APP in
metabolic inflammation. This led us to perform multi-
plex analysis of a wide array of these proinflammatory
cytokine/chemokines and related activation bio-
markers in plasma samples of diabetic and non-
diabetic individuals including determination of the
circulatory fetuin-A levels. To this end, we found that
although plasma fetuin-A levels were comparable be-
tween two groups (P = 0.27), T2D individuals had sig-
nificantly higher plasma concentrations (P ≤ 0.05) of
interferon (IFN)-α2, interleukin (IL)-1α, IL-1β, IL-4,
IL-7, IL-12p40, tumor necrosis factor (TNF)-α, C-C
motif ligand (CCL)-2/macrophage chemoattractant
protein (MCP)-1, CCL-5/regulated on activation,
normal T cell expressed and secreted (RANTES),
CCL-11/eotaxin-1, C-X3-C motif ligand (CX3CL)-1/
fractalkine, epidermal growth factor (EGF), elongation
factor F (EFF)-2, granulocyte-colony stimulating factor
Table 1 Patients’ characteristics and clinical data
Parameter Diabetic Non-diabetic
Lean Overweight Obese Lean Overweight Obese
Total number (N) 11 18 24 24 23 25
Male (N) 7 9 14 10 7 11
Female (N) 4 9 10 14 16 14
Age (Yrs.) 28–58 36–61 23–75 21–61 23–60 28–66
Body mass index (kg/m2) 23.9 ± 1.6 27.7 ± 1.5 33.9 ± 2.5 22.4 ± 1.9 27.1 ± 1.5 34.8 ± 3.6
Body fat percentage 28.9 ± 4.9 33.5 ± 5.9 36.9 ± 5.5 31.3 ± 5.1 33.8 ± 4.6 39.1 ± 5.0
Fasting plasma glucose (mmol/L) 7.9 ± 2.6 7.5 ± 2.8 8.7 ± 2.6 5.1 ± 0.8 5.2 ± 0.4 5.6 ± 0.9
Glycated hemoglobin (HbA1c) (%) 7.4 ± 1.8 6.9 ± 1.3 8.7 ± 1.9 5.5 ± 0.5 5.6 ± 0.4 6.0 ± 1.5
Total cholesterol (mmol/L) 5.1 ± 1.3 5.1 ± 2.0 5.2 ± 1.2 4.9 ± 1.1 5.2 ± 0.9 3.6 ± 0.9
High-density lipoprotein (mmol/L) 1.4 ± 1.0 1.2 ± 0.5 1.2 ± 0.3 1.4 ± 0.4 1.4 ± 0.5 1.2 ± 0.3
Low-density lipoprotein (mmol/L) 3.2 ± 0.7 3.3 ± 1.7 3.2 ± 1.0 3.2 ± 0.8 3.2 ± 0.8 3.5 ± 0.9
Triglycerides (mmol/L) 1.3 ± 0.8 1.6 ± 1.4 2.0 ± 1.6 0.8 ± 0.3 1.1 ± 0.6 1.3 ± 0.6
Hypertension (N) 1 12 12 0 3 7
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Table 2 Plasma analytes (pg/mL) in type-2 diabetic and non-diabetic individuals
Analyte type Diabetic Non-diabetic P
Mean (Samples) SEM Mean (Samples) SEM
Cytokines
IFN-α2 73.56 (n = 52) 8.58 50.99 (n = 56) 7.22 0.05*
IFN-γ 7.11 (n = 49) 0.83 10.96 (n = 66) 1.72 0.07
IL-1α 58.91 (n = 46) 8.48 33.32 (n = 56) 5.84 0.01*
IL-1β 3.42 (n = 46) 0.45 2.04 (n = 58) 0.20 0.004**
IL-1RA 18.92 (n = 52) 2.84 23.72 (n = 63) 5.88 0.49
IL-3 10.10 (n = 24) 2.34 1.45 (n = 14) 0.26 0.10
IL-4 14.67 (n = 49) 2.47 7.35 (n = 60) 0.83 0.003**
IL-5 2.12 (n = 20 0.37 10.22 (n = 19) 2.67 0.004**
IL-6 3.89 (n = 29) 0.74 4.26 (n = 33) 0.79 0.74
IL-7 6.80 (n = 51) 0.93 4.51 (n = 61) 0.52 0.03*
IL-9 2.34 (n = 18) 0.52 1.81 (n = 9) 0.26 0.50
IL-10 4.88 (n = 40) 0.51 6.86 (n = 36) 3.60 0.57
IL-12p40 31.21 (n = 39) 4.59 16.92 (n = 36) 2.05 0.007**
IL-12p70 7.86 (n = 49) 1.10 6.13 (n = 59) 0.63 0.15
IL-13 10.10 (n = 26) 2.34 56.15 (n = 20) 16.72 0.003**
IL-15 3.37 (n = 41) 0.54 2.36 (n = 34) 0.29 0.13
IL-17A 4.14 (n = 40) 0.52 4.40 (n = 50) 0.81 0.80
TNF-α 9.59 (n = 50) 0.78 6.54 (n = 72) 0.42 <0.001***
TNF-β/LT-α 5.66 (n = 20) 1.08 79.58 (n = 16) 31.73 0.01*
Chemokines
CCL-2/MCP-1 209.30 (n = 53) 17.28 158.70 (n = 72) 8.99 0.006**
CCL-3/MIP1-α 7.09 (n = 48) 0.48 21.76 (n = 53) 13.24 0.29
CCL-4/MIP1-β 16.09 (n = 53) 1.40 17.03 (n = 71) 1.94 0.72
CCL-5/RANTES 87146.0 (n = 48) 7136.0 57930.0 (n = 63) 4280.0 <0.001***
CCL-7/MCP-3 10.21 (n = 10) 1.96 75.48 (n = 14) 23.24 0.03*
CCL-11/Eotaxin-1 67.94 (n = 53) 3.62 52.07 (n = 72) 2.18 <0.001***
CCL-22/MDC 385.60 (n = 53) 22.73 441.80 (n = 72) 37.89 0.25
CX3CL-1/Fractalkine 199.80 (n = 53) 17.76 149.80 (n = 70) 8.50 0.007**
CXCL-8/IL-8 4.60 (n = 47) 0.78 6.82 (n = 52) 1.44 0.19
CXCL-10/IP-10 278.70 (n = 53) 29.84 239.10 (n = 72) 15.80 0.21
GRO 1549.0 (n = 53) 139.50 1393.0 (n = 72) 95.70 0.34
Growth Factors
EGF 158.70 (n = 53) 18.57 102.30 (n = 70) 8.17 0.003**
EFF-2 108.60 (n = 53) 9.57 79.30 (n = 72) 4.98 0.004**
FLT-3 L 11.62 (n = 20) 2.92 22.31 (n = 7) 7.87 0.12
G-CSF 39.72 (n = 52) 3.68 31.48 (n = 72) 2.19 0.04*
GM-CSF 11.77 (n = 30) 1.51 9.77 (n = 44) 1.14 0.29
TGF-α 2.02 (n = 21) 0.39 1.20 (n = 22) 0.20 0.07
VEGF 170.40 (n = 53) 16.72 133.10 (n = 71) 13.69 0.08
Platelet Marker
sCD40L 1555.0 (n = 53) 256.90 967.80 (n = 72) 146.80 0.04*
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(G-CSF), and soluble CD40 ligand (sCD40L) as compared
with non-diabetic individuals (data are summarized in
Table 2). Next, plasma fetuin-A levels in T2D patients were
associated negatively (P ≤ 0.05) with proinflammatory cyto-
kines/chemokines and activation biomarkers including IFN-
α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-4, IL-7, IL-9, IL-12p40, IL-
12p70, IL-15, IL-17A,TNF-α, CCL-2/MCP-1, CCL-4/macro-
phage inflammatory protein (MIP)-1β, CCL-11/eotaxin-1,
CCL-22/macrophage-derived chemokine (MDC), C-X-C
motif ligand (CXCL)-8/IL-8, CX3CL-1/Fractalkine, growth-
related oncogene (GRO), EGF, EFF-2, G-CSF, granulocyte-
macrophage colony stimulating factor (GM-CSF), vascular
endothelial growth factor (VEGF), and sCD40L (Table 3). In
non-diabetic individuals, plasma fetuin-A correlated
negatively (P ≤ 0.05) with IL-1β, IL-3, IL-7, IL-9, IL-15, TNF-
α, CCL-2/MCP-1, CCL-22/MDC, CX3CL-1/Fractalkine,
CXCL-10/IP-10, GRO, EFF-2, sCD40L, and VEGF. While, in
this cohort, plasma fetuin-A also correlated positively (P ≤
0.05) with: (a) certain allergic mediators and TH2 cytokines
such as IL-5 and IL-13; (b) a multifunctional TH1 cytokine
called lymphotoxin (LT)-α/TNF-β; and (c) certain chemo-
kines such as CCL-3/MIP-1α, CCL-5/RANTES, and CCL-7/
MCP-3 (Table 3). Both in T2D and non-diabetic individuals,
no association (P > 0.05) was found between plasma fetuin-A
and circulatory IL-6, IL-10, adiponectin, FMS-like tyrosine
kinase 3 ligand (FLT-3 L) and transforming growth factor
(TGF)-α.
Inflammatory cytokines suppress fetuin-A production in
HepG2 cell cultures
Since metformin and angiotensin receptors blockers
have been reported to have lowering effects on circulat-
ing fetuin-A levels [7–9], therefore, possible confound-
ing (suppressive) effects of therapy in our study cohort
may not be ruled out. We asked if the signature inflam-
matory cytokines, related with T2D pathogenesis, alone
were able to suppress the production of fetuin-A in an
in vitro HepG2 cell culture model. To address this, we
treated HepG2 cell cultures (at 70–80 % confluence)
with the typical proinflammatory cytokines and chemo-
kine that are known to be upregulated in metabolic dis-
ease such as obesity and T2D and measured the
expression of fetuin-A in supernatants for comparison
with untreated controls. The treatments with these cyto-
kines/chemokine were carried out using standard
concentrations as available from the literature and these
cytokines/chemokine concentrations also activated the
respective signaling pathways in HepG2 cells (data not
shown). Our data show that fetuin-A production was
significantly reduced (P ≤ 0.05) in HepG2 cell cultures at
24 h following treatments with TNF-α, IL-1β, and IFN-γ
while a non-significant suppression (P > 0.05) was ob-
served after HepG2 cell treatment with MCP-1 and IL-6
as compared with controls (Fig. 1). In addition, time
course experiments were also performed in which both
the proinflammatory (IFN-γ and TNF-α) and antiinflam-
matory (IL-4 and IL-10) cytokines were used to treat
HepG2 cells and fetuin-A was measured in culture
supernatants at 1, 6, 12, 24, and 48 h. These data show
(Additional file 1: Figure S1) that TNF-α treatment re-
sulted in fetuin-A suppression at as early as 12 h and both
IFN-γ and TNF-α suppressed fetuin-A at 24 h and 48 h
while on the other hand, IL-10 induced the expression of
fetuin A at these time points. As expected, no differences
among treatments were observed at earlier (1 h and 6 h)
time points since they may not represent the optimal time
period required for fetuin-A synthesis and extracellular
expression following the cytokine treatments used.
Discussion
Fetuin-A is a relatively new hepatokine and its signifi-
cance as a predictive biomarker in the T2D-associated
metabolic inflammation remains unclear. We report, for
the first time to our knowledge, that the plasma fetuin-A
levels correlate negatively with those of proinflammatory
cytokines/chemokines and activation biomarkers in T2D
individuals which represents the predictive significance
of fetuin-A as a negative APP in T2D. Several lines of
evidence from the previous studies suggest that fetuin-A
synthesis can be divergently regulated in various disease
conditions and thus this hepatokine can serve as a posi-
tive or negative APP during the morbid states. The ele-
vated levels of fetuin-A as found in trauma and ischemic
injury or stroke suggest its role as a positive APP in
those disease conditions [10, 11] whereas, the reduced
fetuin-A levels as observed in endotoxemia, sepsis, and
other inflammatory conditions including pancreatitis,
chronic kidney disease, and rheumatoid arthritis point to
its antiinflammatory or protective role as a negative APP
during these morbid states [12–15]. Our data reveal a
Table 2 Plasma analytes (pg/mL) in type-2 diabetic and non-diabetic individuals (Continued)
Adipokine
Adiponectin 4175.0 (n = 48) 572.30 5044.0 (n = 63) 400.20 0.20
Hepatokine
Fetuin-A/AHSG 677.10 (n = 53) 51.21 612.30 (n = 72) 32.67 0.27
Note: Sample numbers <53 for diabetic and <72 for non-diabetic groups represent the missing data due to undetectable analyte levels in certain samples
*significant; **highly significant; ***extremely significant
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Table 3 Correlation of plasma fetuin-A with inflammatory cytokines, chemokines and activation biomarkers in diabetic and
non-diabetic individuals
Analyte Diabetic Non-diabetic
Pearson r P Pearson r P
Cytokines
IFN-α2 −0.44 (n = 52) 0.001** 0.04 (n = 56) 0.76
IFN-γ −0.41 (n = 49) 0.003** 0.05 (n = 66) 0.68
IL-1α −0.48 (n = 46) 0.001** 0.04 (n = 56) 0.76
IL-1β −0.57 (n = 46) <0.0001*** −0.33 (n = 58) 0.01*
IL-1RA −0.46 (n = 52) 0.001** 0.24 (n = 63) 0.06
IL-3 −0.30 (n = 24) 0.16 −0.79 (n = 14) 0.001**
IL-4 −0.48 (n = 49) 0.001** −0.01 (n = 60) 0.97
IL-5 −0.0008 (n = 20) 0.99 0.58 (n = 19) 0.01*
IL-6 −0.30 (n = 29) 0.12 0.08 (n = 33) 0.67
IL-7 −0.52 (n = 51) <0.0001*** −0.38 (n = 61) 0.003**
IL-9 −0.47 (n = 18) 0.05* −0.68 (n = 9) 0.04*
IL-10 −0.18 (n = 40) 0.26 0.11 (n = 36) 0.52
IL-12p40 −0.45 (n = 39) 0.004** −0.23 (n = 36) 0.17
IL-12p70 −0.41 (n = 49) 0.003** −0.01 (n = 59) 0.92
IL-13 −0.18 (n = 26) 0.39 0.56 (n = 20) 0.01*
IL-15 −0.52 (n = 41) 0.0005*** −0.49 (n = 34) 0.003**
IL-17A −0.54 (n = 40) 0.0004*** −0.24 (n = 50) 0.09
TNF-α −0.66 (n = 50) <0.0001*** −0.33 (n = 72) 0.04*
TNF-β/ LT-α −0.20 (n = 20) 0.46 0.62 (n = 16) 0.01*
Chemokines
CCL-2/MCP-1 −0.69 (n = 53) <0.0001*** −0.52 (n = 72) <0.0001***
CCL-3/MIP1-α 0.01 (n = 48) 0.93 0.30 (n = 53) 0.03*
CCL-4/MIP1-β −0.38 (n = 53) 0.005** 0.20 (n = 71) 0.10
CCL-5/RANTES 0.04 (n = 48) 0.80 0.30 (n = 63) 0.02*
CCL-7/MCP-3 0.16 (n = 10) 0.67 0.80 (n = 14) <0.0001***
CCL-11/Eotaxin-1 −0.42 (n = 53) 0.002** −0.19 (n = 72) 0.10
CCL-22/MDC −0.47 (n = 53) 0.0003*** −0.32 (n = 72) 0.006**
CX3CL-1/Fractalkine −0.56 (n = 53) <0.0001*** −0.30 (n = 70) 0.01*
CXCL-8/IL-8 −0.52 (n = 47) <0.0001*** 0.24 (n = 52) 0.09
CXCL-10/IP-10 −0.22 (n = 53) 0.12 −0.50 (n = 72) <0.0001***
Growth-related oncogene (GRO) −0.69 (n = 53) <0.0001*** −0.29 (n = 72) 0.01*
Adipokine
Adiponectin −0.14 (n = 48) 0.34 −0.01 (n = 63) 0.94
Growth Regulatory Factors
EGF −0.42 (n = 53) 0.002** −0.03 (n = 70) 0.84
EFF-2 −0.61 (n = 53) <0.0001*** −0.29 (n = 72) 0.01*
FLT-3 L −0.32 (n = 20) 0.16 −0.08 (n = 7) 0.87
G-CSF −0.42 (n = 52) 0.002** −0.02 (n = 72) 0.89
GM-CSF −0.45 (n = 30) 0.01* 0.82 (n = 44) 0.06
TGF-α 0.03 (n = 21) 0.89 0.36 (n = 22) 0.10
VEGF −0.53 (n = 53) <0.0001*** −0.29 (n = 71) 0.01*
Platelet Activation Marker
sCD40L −0.64 (n = 53) <0.0001*** −0.48 (n = 72) <0.0001***
Note: Sample numbers <53 for diabetic and <72 for non-diabetic groups represent the missing data due to undetectable analyte levels in certain samples
*significant; **highly significant; ***extremely significant
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strong negative association between fetuin-A levels and
those of signature inflammatory mediators or activation
markers such as TNF-α, IL-1β, IL-7, IL-15, CCL-2, CCL-
4, CXCL-8, CX3CL-1, EFF2, GRO, sCD40L, and VEGF
in T2D patients. The negative association between
fetuin-A and inflammatory mediators shown by our clin-
ical data is further supported by our in vitro studies indi-
cating the reduced fetuin-A production in HepG2 cells
treated with proinflammatory cytokines such as TNF-α,
IL-1β, and IFN-γ. In agreement with our results, early-
stage proinflammatory cytokines such as TNF-α, IL-1β
and IFN-γ were reported to act as negative regulators of
fetuin-A synthesis [12]. The inverse relationship that we
found between fetuin-A levels and proinflammatory
cytokines/chemokines in T2D patients implies that one
would expect to find lower fetuin-A levels in the circula-
tion in the presence of increased proinflammatory cyto-
kines/chemokines and, hence, represent a poor disease
prognosis in inflammatory states. This line of argument
is supported by Metry et al. study showing that low
serum fetuin-A levels were the predictor of a poor out-
come in hemodialysis patients with inflammation [15].
The protective role of fetuin-A as a negative APP is also
substantiated by its function as an opsonin in macro-
phage deactivation at sites of inflammation [16]. On the
other hand, abnormally elevated fetuin-A per se may also
play a pathogenic role by inducing defective insulin re-
ceptor signaling, TLR-4 activation, macrophage migra-
tion, adipocyte dysfunction, hepatic inflammation, and
fibrosis [12, 17].
Our clinical data further show that plasma fetuin-A
levels were associated positively with those of certain
TH2 cytokines (IL-5, IL-13) and C-C chemokines (CCL-
3, CCL-5, and CCL-7); however, only in non-diabetic
individuals. It is not yet clear if these cytokines/chemo-
kines are the positive regulators of fetuin-A synthesis, as
for instance HMGB1 which is a late-acting proinflamma-
tory mediator and was shown to induce fetuin-A in sys-
temic inflammatory conditions [12–15]. In addition,
Polyzos et al. commented on the potentially dual faceted
nature of fetuin-A in Helicobacter pylori infection and
insulin resistance [18]. Trepanowski et al. reported that
circulating fetuin-A levels were elevated in conditions
like obesity, T2D, non-alcoholic fatty liver disease, and
metabolic syndrome while the changes associated with
impaired insulin sensitivity and glucose tolerance [19].
Interestingly, two other studies examined the association
between circulating fetuin-A and prevalent peripheral
arterial disease in T2D patients; however, one study re-
ported a positive association [5] and the other study re-
ported a negative association [20]. Such discrepancies
may relate to the presence of complex confounding fac-
tors in T2D patients such as immunometabolic differ-
ences, co-morbidities, and widely varying therapeutic
regimens. Our study further reveal no association be-
tween plasma fetuin-A levels and those of IL-6 (revealed
by both in vivo and in vitro data), IL-10, adiponectin,
FLT-3 L, and TGF-α in diabetic and non-diabetic indi-
viduals. IL-6 is regarded as a pleiotropic cytokine which
may have both inflammatory and antiinflammatory
effects, IL-10 is a well-known antiinflammatory cytokine,
adiponectin is an adipokine that suppresses metabolic
derangements associated with obesity/T2D, FLT-3 L is a
growth factor for hematopoietic progenitors, and TGF-α
is a mitogenic polypeptide that acts as a ligand for
EGFR/HER-1 to activate signaling pathways for cell pro-
liferation, differentiation, and development [21–23].
Thus, fetuin-A may not be a sensitive predictor to evalu-
ate changes in the pleiotropic and antiinflammatory
cytokines as well as certain adipokines or growth factors
involved in metabolic disease.
Notably, in our study, fetuin-A levels were found to be
comparable between diabetic and non-diabetic individ-
uals whereas those of proinflammatory cytokine/
Fig. 1 Fetuin A in supernatants of HepG2 cell cultures treated with
proinflammatory cytokines. Human hepatocellular carcinoma HepG2
cells were cultured at 37 °C with 5 % CO2 in high-glucose DMEM
medium containing 10 % fetal bovine serum, 100 units/mL penicillin,
and 100 μg/mL streptomycin in 6-well plates at a density of
0.25 × 106 cells/mL until about 70 % confluence and old medium
was replaced with fresh medium. Cell monolayers were then
treated with rhTNF-α (50 ng/mL), rhIL-1β (10 ng/mL), rhIFN-γ
(50 ng/mL), rhMCP-1 (40 ng/mL), and rhIL-6 (100 ng/mL) and
incubated at 37 °C for 24 h. Cell supernatants were collected and
fetuin-A levels were measured using sandwich high-sensitivity ELISA
(Human fetuin-A PicoKineTM ELISA kit, Boster Biological Technology,
USA) following the manufacturer’s instructions as described in Patients
and Methods. Fetuin-A production (mean ± SEM) was found to be
significantly suppressed in HepG2 cells treated with TNF-α (82.05 ±
1.16 ng/mL, P = 0.002), IL-1β (82.73 ± 1.45 ng/mL, P = 0.003), and IFN-γ
(85.70 ± 1.93 ng/mL, P = 0.02) as compared with untreated control
(95.73 ± 1.43 ng/mL). However, fetuin-A production in cells treated
with MCP-1 (84.74 ± 5.02 ng/mL, P = 0.10) and IL-6 (91.66 ± 2.55 ng/mL,
P = 0.24) differed non-sidnificantly from control. The representative data
from three independent determinations are shown
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chemokines or activation/growth mediators (IL-1α/β,
TNF-α, IFN-α2, IL-12, MCP-1, RANTES, eotaxin-1,
fractalkine, EGF, EFF-2, sCD40L, G-CSF, etc.) were
found to be significantly higher in diabetic as com-
pared with non-diabetic individuals which counteracts
the argument of a positive association between fetuin-
A and these inflammatory mediators. Our in vitro
data further support the negative association between
fetuin-A and signature inflammatory cytokines such
as TNF-α, IL-1-β, and IFN-γ and thus rule out the
possible fetuin-A suppressive effects of the antidia-
betic and antihypertensive therapy in T2D patients.
The time course experiments further validate these
data and show that optimal effects of cytokine treat-
ments in HepG2 cells were induced at 24 h and 48 h
whereas TNF-α-mediated suppression of fetuin-A was
observed at as early as 12 h. Interestingly, IL-10 ra-
ther upregulated the expression of fetuin-A in HepG2
cells at 24 h and 48 h time points.
Conclusions
Taken together, our data show that plasma fetuin-A
levels correlated negatively with inflammatory cytokines/
chemokines and various activation biomarkers in T2D
patients, indicating that the circulatory fetuin-A may
have predictive importance as a negative APP in meta-
bolic disease. Nonetheless, further studies will be
required to validate these data in larger patient cohorts.
Additional file
Additional file 1: Figure S1. Fetuin A in supernatants of HepG2 cell
cultures pretreated with proinflammatory and antiinflammatory cytokines.
HepG2 cells were cultured at 37 °C with 5 % CO2 in high-glucose DMEM
medium containing 10 % fetal bovine serum, 100 units/mL penicillin, and
100 μg/mL streptomycin in 6-well plates at a density of 0.25 × 106 cells/mL
until about 70 % confluence was reached and old medium was replaced
with fresh medium. Cell monolayers (triplicate wells) were treated with
proinflammatory cytokines, such as rhIFN-γ (50 ng/mL) and rhTNF-α
(50 ng/mL) as well as antiinflammatory cytokines, such as rhIL-4
(20 ng/mL), and rhIL-10 (30 ng/mL) and cultures were incubated at
37 °C for 1 h, 6 h, 12 h, 24 h, and 48 h for time course analysis.
Cell supernatants were collected and fetuin-A levels were measured
using sandwich high-sensitivity ELISA (Human fetuin-A PicoKineTM
ELISA kit, Boster Biological Technology, USA) following the manufacturer’s
instructions as described in Patients and Methods. Fetuin A levels differed
non-significantly at 1 h (A) and 6 h (B) while TNF-α induced significant
suppression at 12 h (175.4 ± 2.5 ng/mL, P = 0.04) as compared with controls
(185.7 ± 1.7 ng/mL) (C). At 24 h post-treatment, fetuin-A levels (mean ± SEM)
were found to be significantly suppressed in HepG2 cells treated with IFN-γ
(149.1 ± 0.5 ng/mL, P = 0.04) and TNF-α (149.6 ± 1.4 ng/mL, P = 0.05) as
compared with untreated controls (156.8 ± 1.7 ng/mL) (D). Similarly at 48 h,
fetuin-A expression was found to be significantly reduced following
treatments with IFN-γ (122.5 ± 2.2 ng/mL, P = 0.02) and TNF-α (126.0
± 1.7 ng/mL, P = 0.04) as compared with untreated controls (133.8 ±
1.5 ng/mL) (E). On the other hand, treatment with IL-10 upregulated
the fetuin-A expression at both 24 h (164.0 ± 0.5 ng/mL, P = 0.01)
and 48 h (143.0 ± 1.2 ng/mL, P = 0.01) as compared with respective
controls. The representative data from three independent determinations
are shown. (PDF 93 kb)
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